Natco Pharma has received approval from the Central Drugs Standard Control Organisation to manufacture and market a generic semaglutide injection in India. The company plans to launch the product in March 2026. Semaglutide is used as an adjunct to diet and exercise for adults with inadequately controlled type 2 diabetes mellitus. The development is in India’s diabetes treatment market, where demand for advanced medicines remains high.
Regulatory Approval
Natco Pharma secured permission from the national drug regulator to produce and sell the generic version of semaglutide injection. This approval allows the company to enter a growing therapeutic segment in the Indian pharmaceutical market. The launch timeline indicated by the company is March 2026.
Therapeutic Use of Semaglutide
- Semaglutide is prescribed for adults with type 2 diabetes.
- It is used along with diet control and exercise.
- The drug helps in managing blood sugar levels in patients with inadequate control.
Patent Dispute Over Semaglutide
Natco Pharma had earlier moved the Delhi High Court seeking revocation of Novo Nordisk’s patent on semaglutide. Dr Reddy’s Laboratories had also approached the court under the Patents Act and the Commercial Courts Act, challenging Indian Patent No. IN 262697 granted to Novo Nordisk. The case reflects the broader legal contest around access to generic medicines in India.
Market Impact and Industry Context
The approval may strengthen competition in the diabetes drug segment once the product is launched. Natco Pharma’s shares closed lower after the announcement, though the company’s regulatory milestone could influence its future market position. The development is also relevant for exam topics such as drug patents, generic medicines, and pharmaceutical regulation in India.
Last Modified: April 28, 2026